false
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
Immunotherapy and its impact on overall survival i ...
Recording
Recording
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Matt Powell, the chair of the NRG Corpus Committee, discusses the Ruby trial's impact on metastatic endometrial cancer treatment in a conversation with Wendell Nauman. The trial combined immunotherapy with standard chemotherapy, showing significant survival benefits. Powell emphasizes the importance of combining chemotherapy with immunotherapy, especially for MMR-deficient patients. He also addresses subgroup analysis and potential future directions in utilizing immunotherapy, highlighting the need for ongoing research and personalized care. Overall, the discussion underscores the promising advancements in endometrial cancer treatment and the vital role of clinical trials in driving progress in the field.
Keywords
Matt Powell
NRG Corpus Committee
Ruby trial
metastatic endometrial cancer treatment
immunotherapy
Contact
education@igcs.org
for assistance.
×